

Effective January 1, 2025, CMS plans to change coverage for oral-only phosphate lowering therapies (PLTs) drugs for patients with kidney failure. This could jeopardize patients' access to vital medications and raise dialysis treatment costs. Introduced by Reps. Earl L. "Buddy" Carter, Ann McLane Kuster, Carol Miller, and Terri Sewell, the bipartisan Kidney PATIENT Act (H.R. 5074) aims to postpone this change until 2033 or until new intravenous therapies become available.

State and National stakeholders from the kidney community and beyond have called on Washington to act quickly and exclude oral-only phosphate lowering therapies (PLTs) from the End Stage Renal Disease Prospective Payment System or ESRD Bundle.

Support from Stakeholder Groups include:

